# US 2023/0146796 A1 · Triazolone compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0146796 A1
- Document ID: US20230146796A1
- Status: Published application
- Kind: A1
- Application number: 17/914,157
- Filed: 2021-03-25
- Published: 2023-05-11
- Earliest claimed: 2020-03-26
- Assignees: AstraZeneca AB
- Applicants: Astrazeneca AB
- Inventors: Giles Albert Brown; Miles Stuart Congreve; Stephen Philippe Andrews; Jonathan Stephen Mason; Francesca Deflorian; Nigel Alan Swain
- Web page: https://patentgrep.com/patent/US20230146796A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 35/00: Antineoplastic agents
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Described herein are triazalone compounds of Formula (I): and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be useful as adenosine receptor antagonists, for example in the treatment of diseases or conditions mediated by the adenosine receptor, such as cancer, movement disorders, or attention disorders.

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
ring A is saturated, partially unsaturated, or aromatic, and has the structure:
Y1 is N, —CH—, or —C═;
Y2 is O or —CRg═;
wherein Rg is H, halo, —Ra or —ORa;
R1 is halo, C1-3alkyl, —O—C1-3alkyl, —CO2Ra, or —NR7R8;
wherein alkyl is optionally substituted with one or more substituents independently selected from —ORa and halo;
or R1 and Rg together with the atoms to which they are attached form a 5-membered heterocyclyl or heteroaryl having from one to two heteroatoms selected from N and O;
R2 is halo, C1-3alkyl, —O—C1-3alkyl, —CO2Ra, or —NR7R8;
wherein alkyl is optionally substituted with one or more substituents independently selected from —ORa and halo;
R3 is:
R4 is —(CHRc)i—(NRa)j—R5;
R5 is:
(1) C3-8cycloalkyl, aryl, 3- to 8-membered heterocyclyl, or 3- to 8-membered heteroaryl;
wherein heterocyclyl and heteroaryl, independently, include from 1 to 4 heteroatoms independently selected from N, O, and S(O)k;
wherein one or two ring atoms of R5 is optionally replaced by —C(═O )—;
(2) a 6- to 11-membered multicyclic cycloalkyl, aryl, heterocyclyl, or heteroaryl ring system wherein each of heterocyclyl and heteroaryl include from 1 to 4 heteroatoms independently selected from N, O, and S(O)k;
wherein one or two ring atoms of R5 is optionally replaced by —C(═O)—; or
(3) C1-6alkyl, —ORa, —NRaRb, cyano, —OS(O)2—C1-3alkyl, —CO2Ra, —C(O)NRaRb, —NRa—C(O)—ORa, or —O—C(O)—NRaRb;
wherein R5 is optionally substituted with from one to four groups —X—R6;
each X, independently, is a bond, —O—, —NRa—, —S(O)k—, —(CH2)m—, or —C(O)—;
each R6, independently, is H, halo, —ORa, C1-6alkyl, C3-8cycloalkyl, heterocyclyl, heteroaryl, aryl, —CO2Ra, —C(O)NRaRb, —(CH2)n—NRaRb, or cyano;
wherein each of heterocyclyl and heteroaryl includes from 1 to 4 heteroatoms independently selected from N, O, and S(O)k;
wherein one or two ring atoms of each C3-8cycloalkyl, heterocyclyl, heteroaryl, or aryl, independently is optionally replaced by —C(═O )—;
wherein each of alkyl, cycloalkyl, heterocyclyl, heteroaryl, and aryl is optionally substituted with one or more substituents independently selected from —Ra, —ORa, —(CH2)n—NRaRb, and halo;
each R7 and each R8, independently, is Ra;
or R7 and R8 together with the atom to which they are attached form a 3- to 8-membered heterocyclyl optionally substituted with one or more substituents independently selected from —ORa and halo;
each Ra and each Rb, independently, is H, C1-6alkyl, C3-8cycloalkyl, or C4-9cycloalkylalkyl;
wherein each Ra and each Rb, independently, is optionally substituted with one or more substituents independently selected from —OH and halo;
each Rc, independently, is H, halo, C1-3alkyl, or —(CH2)n—NRaRb;
wherein alkyl is optionally substituted with one or more substituents independently selected from —ORa and halo;
each Rd, independently, is halo, cyano, —Ra, or —ORa;
c is 0, 1, 2, or 3;
i is 0, 1, 2, or 3;
j is 0 or 1;
each k, independently, is 0, 1, or 2;
each m, independently, is 1 or 2; and
each n, independently, is 0 or 1.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is a selective adenosine receptor antagonist with respect to CB-1.

### Claim 3 (depends on 2)

The compound of claim 2, wherein the compound has a Ki for at least one of A2aR and A2bR of 100 nM or less, and has a Ki for CB-1 of 10,000 nM or more.

### Claim 4 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R2 is —CH3.

### Claim 5 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
i is 1, 2, or 3; and
each Rc is H.

### Claim 6 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R5 is 5-membered heterocyclyl or 5-membered heteroaryl.

### Claim 7 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
i is 1;
Rc is H; and
R5 is 1,3-oxazolyl optionally substituted with from one to two —CH3.

### Claim 8

A compound of Formula (IIa) or (IIb):
or a pharmaceutically acceptable salt thereof, wherein:
Y1 is N or CH;
Y3 and Y4 together are —CH═N—, —N═CH—, —CH═CH—, or ═CH—O—;
each R1 and each R2, independently, is halo, C1-3alkyl, or —O—C1-3alkyl;
wherein alkyl is optionally substituted with one or more substituents independently selected from —OH and halo;
R4 is —CHRc-R5;
R5 is:
(1) 5- or 6-membered heterocyclyl, or 5- or 6-membered heteroaryl;
wherein heterocyclyl and heteroaryl, independently, include from 1 to 4 heteroatoms independently selected from N, O, and S(O)k;
wherein one or two ring atoms of R5 is optionally replaced by —C(═O )—;
wherein heterocyclyl and heteroaryl are optionally substituted with one or more substituents independently selected from halo, —Re, and —ORe; or
(2) H, halo, or C1-3alkyl;
wherein alkyl is optionally substituted with one or more substituents independently selected from —OH and halo;
each Ra and each Rb, independently, is H, C1-6alkyl, C3-8cycloalkyl, or C4-9cycloalkylalkyl;
wherein each Ra and each Rb, independently, is optionally substituted with one or more substituents independently selected from —OH and halo;
Rc is H, halo, C1-3alkyl, or —(CH2)n—NRaRb;
wherein alkyl is optionally substituted with one or more substituents independently selected from —ORa and halo;
Rd is H or halo;
each Re, independently, is H or C1-6alkyl;
wherein alkyl is optionally substituted with one or more substituents independently selected from —OH and halo; and
n is 0 or 1.

### Claim 9 (depends on 8)

The compound of claim 8 of Formula (IIa), or a pharmaceutically acceptable salt thereof, wherein:
Y1 is N; and
R1 and R2 are each independently —CH3.

### Claim 10 (depends on 8)

The compound of claim 8 of Formula (IIb), wherein:
R2 is —CH3; and
R5 is 5- or 6-membered heteroaryl.

### Claim 11 (depends on 8)

The compound of claim 8 of Formula (IIa) or Formula (IIb), or a pharmaceutically acceptable salt thereof, wherein:
Rc is H; and
R5 is C1-3alkyl optionally substituted with from one to three fluoro.

### Claim 12

A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
5-amino-8-[(cis)-2,6-dimethylmorpholin-4-yl]-7-phenyl-2-(3,3,3-trifluoropropyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-8-[(cis)-2,6-dimethylmorpholin-4-yl]-2-(3-fluoropropyl)-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-2-(3,3-difluoropropyl)-8-[(cis)-2,6-dimethylmorpholin-4-yl]-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-8-[(cis)-2,6-dimethylmorpholin-4-yl]-7-phenyl-2-propyl-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-8-[(cis)-2,6-dimethylmorpholin-4-yl]-7-(4-fluorophenyl)-2-(3,3,3-trifluoropropyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-8-[(cis)-2,6-dimethylmorpholin-4-yl]-7-(4-fluorophenyl)-2-propyl-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-8-[(cis)-2,6-dimethylmorpholin-4-yl]-2-[[(2S)-1-methylpyrrolidin-2-yl]methyl]-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-8-[(cis)-2,6-dimethylmorpholin-4-yl]-7-phenyl-2-[[(2R)-tetrahydrofuran-2-yl]methyl]-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-8-[(cis)-2,6-dimethylmorpholin-4-yl]-7-phenyl-2-[2-(1-piperidyl)ethyl]-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-8-[(cis)-2,6-dimethylmorpholin-4-yl]-2-[[(3S)-morpholin-3-yl]methyl]-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-8-[(cis)-2,6-dimethylmorpholin-4-yl]-2-[[(3R)-morpholin-3-yl]methyl]-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-8-[(cis)-2,6-dimethylmorpholin-4-yl]-2-[[(3S)-4-methylmorpholin-3-yl]methyl]-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-8-[(cis)-2,6-dimethylmorpholin-4-yl]-2-[[(3R)-4-methylmorpholin-3-yl]methyl]-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-8-[(cis)-2,6-dimethylmorpholin-4-yl]-2-[(5-fluoro-2-pyridyl)methyl]-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-8-[(cis)-2,6-dimethylmorpholin-4-yl]-2-[(2-methoxy-3-pyridyl)methyl]-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-8-[(cis)-2,6-dimethylmorpholin-4-yl]-7-phenyl-2-(pyridazin-3-ylmethyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-8-[(cis)-2,6-dimethylmorpholin-4-yl]-7-phenyl-2-(2-phenylethyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-8-[(cis)-2,6-dimethyl-3,6-dihydro-2H-pyran-4-yl]-7-phenyl-2-(3,3,3-trifluoropropyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-8-[(cis)-2,6-dimethyltetrahydropyran-4-yl]-7-phenyl-2-(3,3,3-trifluoropropyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-2-[(5-fluoro-2-pyridyl)methyl]-8-(4-hydroxy-3,5-dimethyl-phenyl)-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-7-(4-fluorophenyl)-8-(4-methyl-1,3-benzoxazol-6-yl)-2-(3,3,3-trifluoropropyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-2-[(5-chloro-2-pyridyl)methyl]-7-(4-fluorophenyl)-8-(4-methyl-1,3-benzoxazol-6-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-7-(4-fluorophenyl)-8-(4-methyl-1,3-benzoxazol-6-yl)-2-[(5-methyl-2-pyridyl)methyl]-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-2-[(5-fluoro-2-pyridyl)methyl]-8-(7-methyl-1H-indazol-5-yl)-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-2-[(5-fluoro-2-pyridyl)methyl]-8-(7-methyl-1H-benzimidazol-5-yl)-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-8-(4-methyl-1,3-benzoxazol-6-yl)-2-[(5-methyloxazol-4-yl)methyl]-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-2-[(2,5-dimethyloxazol-4-yl)methyl]-7-(4-fluorophenyl)-8-(4-methyl-1,3-benzoxazol-6-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-7-(4-fluorophenyl)-8-(7-methyl-1H-indazol-5-yl)-2-[(5-methyloxazol-4-yl)methyl]-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-8-(7-methyl-1H-indazol-5-yl)-2-[(5-methyloxazol-4-yl)methyl]-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-8-(7-methyl-1H-indazol-5-yl)-2-[(5-methyloxazol-4-yl)methyl]-7-(2,3,4,5,6-pentadeuteriophenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one;
5-amino-8-(7-chloro-1H-indazol-5-yl)-2-[(5-methyloxazol-4-yl)methyl]-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-3-one; and
5-amino-8-(7-methyl-1H-indol-5-yl)-2-[(5-methyloxazol-4-yl)methyl]-7-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-3-one.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A pharmaceutical composition comprising a compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

Use of a compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, for the treatment of a disease or condition mediated by the adenosine receptor.

### Claim 15 (depends on 14)

The use of claim 14, wherein the disease or condition mediated by the adenosine receptor is lung cancer, pancreatic cancer, prostate cancer, ovarian cancer, cervical cancer, colorectal cancer, breast cancer, brain cancer, gastric cancer, liver cancer, renal cancer, endometrial cancer, thyroid cancer, bladder cancer, glial cancer, melanoma, or other solid tumor.
